Drug Manufacturers - Specialty & Generic | Healthcare
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Market Cap
53868642304
Current Price
247.02
52 Week Range
95.2 - 250.48
Previous Close
224.57
Open
226.12
Sector
Healthcare
Address
8-2-334, SDE Serene Chambers, 6th Floor Road No.5, Avenue 7 Banjara Hills, Hyderabad, 500034, India
Phone
+91-40235-41142
Fax
+91-40235-41152
Website
https://www.suven.com
Day Low
226.12
Day High
247.02
Dividend Yield
PE Ratio
Earnings Per Share
-7.46
Beta
0.817
EBITDA
-1522297984
Book Value
8.81
EPS
Name | Title | Age | Year Born |
---|---|---|---|
Mr. Venkateswarlu Jasti M.Pharm. M.S. | CEO, MD & Executive Chairman | 75 | 1949 |
Ms. Sudharani Jasti B.Sc. | Whole-Time Director | 70 | 1954 |
Mr. M. Mohan Kumar C.M.A. | Chief Financial Officer | - | - |
Mr. Kundan Kumar Jha | Company Secretary & Compliance Officer | - | - |
Ms. Kalyani Jasti | President of US Operations | 45 | 1979 |
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Find high-momentum stocks with strong forward PE ratios and moderate volatility for aggressive investors.
Explore stocks with high dividend yields and low debt-to-equity ratios for stable income.
Discover large-cap stocks with stable beta for lower volatility and reliable returns.
Find undervalued stocks with reasonable forward PE and market cap for value investors.
Discover stocks with strong 5-year revenue growth trading near their 52-week lows, ideal for long-term investment.
Explore high-beta stocks with significant price movement potential for risk-tolerant investors.
Discover mid to large-cap stocks with strong growth potential and attractive valuations.
Find affordable stocks with consistent dividend payouts for income-focused investors.